STOCK TITAN

GoodRx Reports Third Quarter 2024 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags

GoodRx Holdings reported its Q3 2024 financial results with revenue of $195.3 million, up 8% year-over-year, and net income of $4.0 million. Key highlights include a net income margin of 2.0%, Adjusted EBITDA of $65.0 million, and operating cash flow of $86.9 million. Prescription transactions revenue increased 4% to $140.4 million, while pharma manufacturer solutions revenue grew 77% to $28.1 million. The company expects Q4 2024 revenue of approximately $200 million with an Adjusted EBITDA margin of ~34%. For full-year 2024, GoodRx projects revenue of ~$794 million and Adjusted EBITDA between $255-260 million.

GoodRx Holdings ha riportato i risultati finanziari del terzo trimestre 2024 con un fatturato di 195,3 milioni di dollari, in aumento dell'8% rispetto all'anno precedente, e un utile netto di 4,0 milioni di dollari. I punti salienti includono un margine di utile netto del 2,0%, un EBITDA rettificato di 65,0 milioni di dollari e un flusso di cassa operativo di 86,9 milioni di dollari. Le entrate delle transazioni di prescrizione sono aumentate del 4% a 140,4 milioni di dollari, mentre i ricavi delle soluzioni per i produttori farmaceutici sono cresciuti del 77% a 28,1 milioni di dollari. L'azienda prevede un fatturato per il quarto trimestre 2024 di circa 200 milioni di dollari con un margine EBITDA rettificato di ~34%. Per l'intero anno 2024, GoodRx prevede un fatturato di ~794 milioni di dollari e un EBITDA rettificato compreso tra 255 e 260 milioni di dollari.

GoodRx Holdings reportó sus resultados financieros del tercer trimestre de 2024 con ingresos de 195.3 millones de dólares, un aumento del 8% en comparación con el año anterior, y una utilidad neta de 4.0 millones de dólares. Los aspectos destacados incluyen un margen de utilidad neta del 2.0%, un EBITDA ajustado de 65.0 millones de dólares y un flujo de efectivo operativo de 86.9 millones de dólares. Los ingresos por transacciones de recetas aumentaron un 4% a 140.4 millones de dólares, mientras que los ingresos por soluciones de fabricantes farmacéuticos crecieron un 77% a 28.1 millones de dólares. La empresa espera ingresos de aproximadamente 200 millones de dólares para el cuarto trimestre de 2024, con un margen de EBITDA ajustado de ~34%. Para todo el año 2024, GoodRx proyecta ingresos de aproximadamente 794 millones de dólares y un EBITDA ajustado entre 255 y 260 millones de dólares.

GoodRx Holdings는 2024년 3분기 재무 결과를 보고했으며, 매출은 1억 9,530만 달러로, 전년 대비 8% 증가했으며, 순이익은 400만 달러입니다. 주요 하이라이트로는 순이익률 2.0%, 조정된 EBITDA 6,500만 달러, 운영 현금 흐름 8,690만 달러가 포함됩니다. 처방 거래 수익은 4% 증가하여 1억 4,040만 달러에 달했으며, 제약 제조업체 솔루션 수익은 77% 증가하여 2,810만 달러가 되었습니다. 회사는 2024년 4분기 매출을 약 2억 달러로 예상하며, 조정된 EBITDA 마진은 ~34%가 될 것으로 보입니다. 2024년 전체 연도에 대해 GoodRx는 약 7억 9,400만 달러의 매출과 2억 5,500만에서 2억 6,000만 달러 사이의 조정된 EBITDA를 예상하고 있습니다.

GoodRx Holdings a annoncé ses résultats financiers pour le troisième trimestre 2024, avec un chiffre d'affaires de 195,3 millions de dollars, en hausse de 8 % par rapport à l'année précédente, et un bénéfice net de 4,0 millions de dollars. Les éléments clés incluent une marge bénéficiaire nette de 2,0 %, un EBITDA ajusté de 65,0 millions de dollars et un flux de trésorerie opérationnel de 86,9 millions de dollars. Les revenus issus des transactions de prescriptions ont augmenté de 4 % pour atteindre 140,4 millions de dollars, tandis que les revenus des solutions pour les fabricants pharmaceutiques ont crû de 77 % pour atteindre 28,1 millions de dollars. L'entreprise prévoit un chiffre d'affaires d'environ 200 millions de dollars pour le quatrième trimestre 2024, avec une marge d'EBITDA ajusté d'environ 34 %. Pour l'année complète 2024, GoodRx prévoit un chiffre d'affaires d'environ 794 millions de dollars et un EBITDA ajusté compris entre 255 et 260 millions de dollars.

GoodRx Holdings hat seine finanziellen Ergebnisse für das 3. Quartal 2024 veröffentlicht, mit einem Umsatz von 195,3 Millionen Dollar, was einem Anstieg von 8% im Vergleich zum Vorjahr entspricht, und einem Nettogewinn von 4,0 Millionen Dollar. Zu den wichtigsten Höhepunkten gehören eine Nettogewinnmarge von 2,0%, ein bereinigtes EBITDA von 65,0 Millionen Dollar und ein operativer Cashflow von 86,9 Millionen Dollar. Die Einnahmen aus Verschreibungen stiegen um 4% auf 140,4 Millionen Dollar, während der Umsatz aus Lösungen für Pharmahersteller um 77% auf 28,1 Millionen Dollar wuchs. Das Unternehmen erwartet für das 4. Quartal 2024 einen Umsatz von etwa 200 Millionen Dollar mit einer bereinigten EBITDA-Marge von ~34%. Für das gesamte Jahr 2024 prognostiziert GoodRx einen Umsatz von etwa 794 Millionen Dollar und ein bereinigtes EBITDA zwischen 255 und 260 Millionen Dollar.

Positive
  • Revenue increased 8% YoY to $195.3 million
  • Net income of $4.0 million compared to prior year loss of $38.5 million
  • Pharma manufacturer solutions revenue grew 77% to $28.1 million
  • Operating cash flow increased to $86.9 million from $60.3 million YoY
  • Adjusted EBITDA margin improved to 33.3% from 28.1% YoY
Negative
  • Subscription revenue decreased 8% to $21.3 million
  • Full year 2024 revenue expectations lowered from previous guidance
  • Kroger Savings Club partnership ended, contributing $0 revenue vs $2.1M in Q3 2023

Insights

The Q3 2024 results show mixed performance. Revenue grew 8% to $195.3M, with net income of $4.0M, marking a significant turnaround from last year's $38.5M loss. The pharma manufacturer solutions segment showed impressive growth of 77%, reaching $28.1M.

Key metrics demonstrate operational efficiency with Adjusted EBITDA margin expanding to 33.3% from 28.1%. The strong cash position of $423.8M and successful debt refinancing provide financial flexibility. However, the lowered full-year revenue guidance and challenges in the retail pharmacy environment suggest some headwinds.

The company's share repurchase program and disciplined capital allocation strategy indicate confidence in long-term prospects, though near-term growth may be moderating.

GoodRx's market positioning remains solid with over 7 million consumers using their prescription-related offerings. The 7% increase in Monthly Active Consumers signals healthy organic growth. However, the sunset of the Kroger Savings Club partnership impacted subscription revenue, highlighting dependency risks on key partnerships.

The projected 20% growth in pharma manufacturer solutions for Q4 2024 and 20%+ for 2025 suggests strong momentum in this high-margin segment. The company's focus on medicine affordability and accessibility aligns well with current healthcare trends, though competitive pressures and pharmacy environment challenges require monitoring.

SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024.

Third Quarter 2024 Highlights

  • Revenue1 and Adjusted Revenue1 of $195.3 million
  • Net income of $4.0 million; Net income margin of 2.0%
  • Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4%
  • Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3%
  • Net cash provided by operating activities of $86.9 million
  • Exited the quarter with over 7 million consumers of prescription-related offerings2

“In a world where there is increasing attention on medicine affordability and access, we believe the strategic high ground belongs to brands and companies that benefit patients and remove friction from a complicated healthcare ecosystem. At GoodRx, that's our North Star and we believe it's enabled us to gain share in our category and strengthen our value proposition throughout 2024,” said Scott Wagner, Interim Chief Executive Officer of GoodRx. “We continue to build momentum on our programs with brand manufacturers and anticipate about 20% year-over-year top-line growth in our pharma manufacturer solutions offering for Q4 2024, and 20%+ for full year 2025. And while the retail pharmacy environment is experiencing short-term choppiness, we believe we continue to provide invaluable support to our partners by driving traffic and helping them meet their merchandising goals.”

1

Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. For the third quarter of 2024, revenue, the most directly comparable financial measure calculated in accordance with GAAP, was equal to Adjusted Revenue and we expect revenue to equal Adjusted Revenue for the fourth quarter and full year of 2024. Revenue excluding the $10.0 million client contract termination payment represents Adjusted Revenue for the third quarter and full year 2023. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and reconciliations to the most directly comparable GAAP measures.

2

Sum of Monthly Active Consumers (MACs) for Q3'24 and subscribers to our subscription plans as of September 30, 2024. Refer to Key Operating Metrics below for definitions of Monthly Active Consumers and subscription plans.

Third Quarter 2024 Financial Overview (all comparisons are made to the same period of the prior year unless otherwise noted):

Revenue1 increased 8% to $195.3 million compared to $180.0 million. Adjusted Revenue1 increased 3% to $195.3 million compared to $190.0 million.

Prescription transactions revenue increased 4% to $140.4 million compared to $135.4 million, primarily driven by a 7% increase in Monthly Active Consumers principally from organic growth, including expansion of our integrated savings program.

Subscription revenue decreased 8% to $21.3 million compared to $23.2 million, primarily driven by a decrease in the number of subscription plans due to the sunset of our partnership subscription program, Kroger Savings Club. Kroger Savings Club contributed $2.1 million of subscription revenue in the third quarter 2023 and nil for the same period of 2024.

Pharma manufacturer solutions revenue increased 77% to $28.1 million compared to $15.9 million, primarily driven by a $10.0 million client contract termination payment recognized as a reduction of revenue in the prior year quarter in connection with the restructuring of our pharma manufacturer solutions offering in the second half of 2023 (the “restructuring”). The year-over-year change was also driven by organic growth as we continued to expand our market penetration with pharma manufacturers and other customers, including ongoing growth in our point of sale discount programs, which fully offset the $2.5 million decrease in revenue contribution from vitaCare Prescription Services, Inc., a solution we de-prioritized in connection with the restructuring.

Net income was $4.0 million compared to a net loss of $38.5 million. The year-over year change was primarily driven by restructuring related costs including accelerated amortization of certain intangible assets incurred in the prior year quarter in connection with the restructuring and the subsequent run rate savings. The impact from these drivers was partially offset by debt refinancing costs incurred in the current year quarter and changes in our income tax position. Net income margin was 2.0% compared to a net loss margin of 21.4%. Adjusted Net Income1 was $31.9 million compared to Adjusted Net Income1 of $25.5 million.

Adjusted EBITDA1 was $65.0 million compared to $53.5 million. The year-over-year change was primarily driven by top-line growth and run rate savings as a result of the restructuring. Adjusted EBITDA Margin1 was 33.3% compared to 28.1%.

Cash Flow and Capital Allocation

Net cash provided by operating activities in the third quarter was $86.9 million compared to $60.3 million in the comparable period last year, driven by an increase in net income after adjusting for non-cash items and changes in operating assets and liabilities. Changes in operating assets and liabilities were principally driven by the timing of payments of prepaid services, accounts payable and accrued expenses, income tax payments and refunds, as well as collections of accounts receivable. As of September 30, 2024, we had cash and cash equivalents of $423.8 million and total outstanding debt of $500.0 million.

As previously announced, in July 2024, we refinanced our debt to, among other things, establish a new $500.0 million term loan facility that matures on July 10, 2029 and extend the maturity date on $88.0 million of our $100.0 million revolving credit facility to April 10, 2029. Concurrent with the refinance, we repaid our then-existing term loan in full using all the proceeds from the new term loan (either in cash or via conversion) and cash on hand.

We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating shareholder value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also providing flexibility to navigate near-term challenges.

Share Repurchases

During the third quarter of 2024, we repurchased 0.8 million shares of Class A common stock for an aggregate of $5.3 million. As of September 30, 2024, we had $290.2 million of unused authorized share repurchase capacity under our $450.0 million share repurchase program that does not expire.

Guidance

For the fourth quarter and full year 2024, management is anticipating the following:

$ in millions

4Q 2024

4Q 2023

YoY Change

Revenue1

~$200

$196.6

~2%

Adjusted Revenue1

~$200

$196.6

~2%

Adjusted EBITDA Margin3

~34%

29.1%

~490 bps

 

$ in millions

FY 2024

FY 2023

YoY Change

Revenue1

~$794

$750.3

~6%

Adjusted Revenue1

~$794

$760.3

~4%

Adjusted EBITDA3

$255 - $260

$217.4

17% - 20%

“For the fourth quarter of 2024, we are guiding to revenue and Adjusted Revenue of approximately $200 million and Adjusted EBITDA Margin of about 34%,” said Karsten Voermann, Chief Financial Officer. “While our full year 2024 revenue and Adjusted Revenue expectations are lower than what we previously indicated, we are confident we can achieve strong Adjusted EBITDA of $255 to $260 million, up over 17% from 2023, and Adjusted EBITDA Margin of over 32%, up more than 340 basis points from 2023.”

“Our balance sheet and liquidity remained robust in the third quarter of 2024. Our capital allocation priorities are unchanged and we will continue to prioritize high return investments and maximizing value for shareholders,” concluded Voermann.

3

Adjusted EBITDA Margin is Adjusted EBITDA divided by Adjusted Revenue. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. We have not reconciled our Adjusted EBITDA and Adjusted EBITDA Margin guidance to GAAP net income or loss and GAAP net income or loss margin, respectively, because we do not provide guidance for such GAAP measures due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted EBITDA and Adjusted EBITDA Margin and their respective most directly comparable GAAP measures. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our future GAAP net income or loss and GAAP net income or loss margin.

Investor Conference Call and Webcast

GoodRx management will host a conference call and webcast today, November 7, 2024, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.

To access the conference call, please pre-register using the following link:

https://register.vevent.com/register/BIe2e0d2e5ebec4cc3ae9f66e59492a2f5

Registrants will receive a confirmation with dial-in details and a unique passcode required to join.

The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

About GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, industry and business trends, including the anticipated impact of retail pharmacy closures, our value proposition, consumer and partner perception and our position in the healthcare ecosystem/industry, our integrated savings programs, our business strategy and our ability to execute on our strategic priorities and value creation, our plans, market opportunity and long-term growth prospects, our capital allocation priorities, and our objectives for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants; our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infectious disease, such as COVID-19; the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cybersecurity; risks related to a decrease in consumer willingness to receive correspondence or any technical, legal or any other restrictions to send such correspondence; risks related to any failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to attract, develop, motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or other disruptions in the operations of these parties on which we depend; risks related to climate change; the increasing focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural disasters or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; risks related to the recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending which may adversely affect our business, financial condition and results of operations; as well as the other important factors discussed in the section entitled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Key Operating Metrics

Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who use our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are averaged over the number of calendar months in such period. Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition.

Subscription plans represent the ending subscription plan balance across both of our subscription offerings, GoodRx Gold and Kroger Savings Club, which sunset in July 2024. Each subscription plan may represent more than one subscriber since family subscription plans may include multiple members.

We exited the third quarter of 2024 with over 7 million prescription-related consumers that used GoodRx across our prescription transactions and subscription offerings. Our prescription-related consumers represent the sum of Monthly Active Consumers for the three months ended September 30, 2024 and subscribers to our subscription plans as of September 30, 2024.

 

Three Months Ended

(in millions)

September 30,
2024

 

June 30,
2024

 

March 31,
2024

 

December 31,
2023

 

September 30,
2023

 

June 30,
2023

 

March 31,
2023

Monthly Active Consumers

6.5

 

6.6

 

6.7

 

6.4

 

6.1

 

6.1

 

6.1

 

As of

(in thousands)

September 30,
2024

 

June 30,
2024

 

March 31,
2024

 

December 31,
2023

 

September 30,
2023

 

June 30,
2023

 

March 31,
2023

Subscription plans

701

 

696

 

778

 

884

 

930

 

969

 

1,007

GoodRx Holdings, Inc.

Condensed Consolidated Balance Sheets (Unaudited)

 

(in thousands, except par values)

 

 

 

 

 

September 30, 2024

 

December 31, 2023

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

423,777

 

 

$

672,296

 

Accounts receivable, net

 

130,803

 

 

 

143,608

 

Prepaid expenses and other current assets

 

72,220

 

 

 

56,886

 

Total current assets

 

626,800

 

 

 

872,790

 

Property and equipment, net

 

13,625

 

 

 

15,932

 

Goodwill

 

410,769

 

 

 

410,769

 

Intangible assets, net

 

54,061

 

 

 

60,898

 

Capitalized software, net

 

119,898

 

 

 

95,439

 

Operating lease right-of-use assets, net

 

28,842

 

 

 

29,929

 

Deferred tax assets, net

 

65,910

 

 

 

65,268

 

Other assets

 

34,941

 

 

 

37,775

 

Total assets

$

1,354,846

 

 

$

1,588,800

 

Liabilities and stockholders' equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

12,391

 

 

$

36,266

 

Accrued expenses and other current liabilities

 

92,677

 

 

 

71,329

 

Current portion of debt

 

3,750

 

 

 

8,787

 

Operating lease liabilities, current

 

5,543

 

 

 

6,177

 

Total current liabilities

 

114,361

 

 

 

122,559

 

Debt, net

 

487,593

 

 

 

647,703

 

Operating lease liabilities, net of current portion

 

47,681

 

 

 

48,403

 

Other liabilities

 

8,777

 

 

 

8,177

 

Total liabilities

 

658,412

 

 

 

826,842

 

Stockholders' equity

 

 

 

Preferred stock, $0.0001 par value

 

 

 

 

 

Common stock, $0.0001 par value

 

38

 

 

 

40

 

Additional paid-in capital

 

2,144,149

 

 

 

2,219,321

 

Accumulated deficit

 

(1,447,753

)

 

 

(1,457,403

)

Total stockholders' equity

 

696,434

 

 

 

761,958

 

Total liabilities and stockholders' equity

$

1,354,846

 

 

$

1,588,800

 

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

195,251

 

 

$

179,958

 

 

$

593,741

 

 

$

553,621

 

Costs and operating expenses:

 

 

 

 

 

 

 

Cost of revenue, exclusive of depreciation and amortization presented separately below

 

11,684

 

 

 

18,721

 

 

 

36,022

 

 

 

51,755

 

Product development and technology

 

30,139

 

 

 

39,611

 

 

 

92,010

 

 

 

103,804

 

Sales and marketing

 

89,867

 

 

 

91,615

 

 

 

273,285

 

 

 

247,577

 

General and administrative

 

25,619

 

 

 

35,317

 

 

 

94,316

 

 

 

95,144

 

Depreciation and amortization

 

17,535

 

 

 

33,024

 

 

 

50,442

 

 

 

64,060

 

Total costs and operating expenses

 

174,844

 

 

 

218,288

 

 

 

546,075

 

 

 

562,340

 

Operating income (loss)

 

20,407

 

 

 

(38,330

)

 

 

47,666

 

 

 

(8,719

)

Other expense, net:

 

 

 

 

 

 

 

Other expense

 

(2,660

)

 

 

(2,200

)

 

 

(2,660

)

 

 

(4,008

)

Loss on extinguishment of debt

 

(2,077

)

 

 

 

 

 

(2,077

)

 

 

 

Interest income

 

4,797

 

 

 

8,649

 

 

 

18,686

 

 

 

23,697

 

Interest expense

 

(12,355

)

 

 

(14,720

)

 

 

(41,564

)

 

 

(41,907

)

Total other expense, net

 

(12,295

)

 

 

(8,271

)

 

 

(27,615

)

 

 

(22,218

)

Income (loss) before income taxes

 

8,112

 

 

 

(46,601

)

 

 

20,051

 

 

 

(30,937

)

Income tax (expense) benefit

 

(4,147

)

 

 

8,106

 

 

 

(10,401

)

 

 

47,938

 

Net income (loss)

$

3,965

 

 

$

(38,495

)

 

$

9,650

 

 

$

17,001

 

Earnings (loss) per share:

 

 

 

 

 

 

 

Basic

$

0.01

 

 

$

(0.09

)

 

$

0.03

 

 

$

0.04

 

Diluted

$

0.01

 

 

$

(0.09

)

 

$

0.02

 

 

$

0.04

 

Weighted average shares used in computing earnings (loss) per share:

 

 

 

 

 

 

 

Basic

 

379,667

 

 

 

413,437

 

 

 

385,553

 

 

 

412,698

 

Diluted

 

388,504

 

 

 

413,437

 

 

 

393,477

 

 

 

416,450

 

 

 

 

 

 

 

 

 

Stock-based compensation included in costs and operating expenses:

 

 

 

 

 

 

 

Cost of revenue

$

86

 

 

$

146

 

 

$

226

 

 

$

487

 

Product development and technology

 

6,384

 

 

 

6,829

 

 

 

18,491

 

 

 

22,952

 

Sales and marketing

 

9,725

 

 

 

10,273

 

 

 

27,248

 

 

 

11,665

 

General and administrative

 

10,186

 

 

 

15,398

 

 

 

32,102

 

 

 

40,938

 

GoodRx Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

(in thousands)

 

 

 

 

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

Cash flows from operating activities

 

 

 

Net income

$

9,650

 

 

$

17,001

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

50,442

 

 

 

64,060

 

Loss on extinguishment of debt

 

2,077

 

 

 

 

Amortization of debt issuance costs

 

2,076

 

 

 

2,539

 

Non-cash operating lease expense

 

2,981

 

 

 

3,022

 

Stock-based compensation expense

 

78,067

 

 

 

76,042

 

Deferred income taxes

 

(642

)

 

 

(57,989

)

Loss on operating lease assets

 

 

 

 

374

 

Loss on disposal of capitalized software

 

 

 

 

7,615

 

Loss on minority equity interest investment

 

 

 

 

4,008

 

Changes in operating assets and liabilities

 

 

 

Accounts receivable

 

12,805

 

 

 

(4,005

)

Prepaid expenses and other assets

 

(12,268

)

 

 

(29,867

)

Accounts payable

 

(23,167

)

 

 

14,515

 

Accrued expenses and other current liabilities

 

19,778

 

 

 

26,071

 

Operating lease liabilities

 

(3,250

)

 

 

(1,460

)

Other liabilities

 

600

 

 

 

498

 

Net cash provided by operating activities

 

139,149

 

 

 

122,424

 

Cash flows from investing activities

 

 

 

Purchase of property and equipment

 

(1,078

)

 

 

(634

)

Capitalized software

 

(52,625

)

 

 

(42,260

)

Net cash used in investing activities

 

(53,703

)

 

 

(42,894

)

Cash flows from financing activities

 

 

 

Proceeds from long-term debt

 

472,033

 

 

 

 

Payments on long-term debt

 

(639,038

)

 

 

(5,272

)

Payments of debt issuance costs

 

(2,673

)

 

 

 

Repurchases of Class A common stock

 

(158,657

)

 

 

(26,149

)

Proceeds from exercise of stock options

 

18,435

 

 

 

4,385

 

Employee taxes paid related to net share settlement of equity awards

 

(24,922

)

 

 

(15,403

)

Proceeds from employee stock purchase plan

 

857

 

 

 

649

 

Net cash used in financing activities

 

(333,965

)

 

 

(41,790

)

Net change in cash and cash equivalents

 

(248,519

)

 

 

37,740

 

Cash and cash equivalents

 

 

 

Beginning of period

 

672,296

 

 

 

757,165

 

End of period

$

423,777

 

 

$

794,905

 

Non-GAAP Financial Measures

Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Margin and Adjusted Earnings Per Share are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted operating income. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures."

We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or future underlying performance of the business.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, charitable stock donation, gain on sale of business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of Adjusted Revenue.

We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, charitable stock donation, gain on sale of business, other expense, and as further adjusted for estimated income tax on such adjusted items. Our adjusted taxes also excludes (i) the valuation allowance recorded against certain of our net deferred tax assets that was recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.

Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted, depending on whether we have adjusted net loss or adjusted net income, respectively.

We also assess our performance by evaluating each cost and operating expense on our condensed consolidated statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses, amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal settlement expenses, loss on operating lease assets, charitable stock donation, and gain on sale of business. Adjusted operating income is Adjusted Revenue less non-GAAP costs and operating expenses.

We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are also key measures we use to assess our financial performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Earnings Per Share are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.

The following table presents a reconciliation of net (loss) income and revenue, the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted EBITDA and Adjusted Revenue, respectively, and presents net (loss) income margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

(dollars in thousands)

 

Three Months Ended
March 31,

 

Three Months Ended
June 30,

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

2023

 

 

 

2023

 

Net (loss) income

$

(1,009

)

 

$

(3,290

)

 

$

6,694

 

 

$

58,786

 

 

$

3,965

 

 

$

(38,495

)

 

$

9,650

 

 

$

17,001

 

 

$

(25,869

)

 

$

(8,868

)

Adjusted to exclude the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

(7,555

)

 

 

(7,234

)

 

 

(6,334

)

 

 

(7,814

)

 

 

(4,797

)

 

 

(8,649

)

 

 

(18,686

)

 

 

(23,697

)

 

 

(8,474

)

 

 

(32,171

)

Interest expense

 

14,643

 

 

 

13,133

 

 

 

14,566

 

 

 

14,054

 

 

 

12,355

 

 

 

14,720

 

 

 

41,564

 

 

 

41,907

 

 

 

14,821

 

 

 

56,728

 

Income tax expense (benefit)

 

1,302

 

 

 

6,886

 

 

 

4,952

 

 

 

(46,718

)

 

 

4,147

 

 

 

(8,106

)

 

 

10,401

 

 

 

(47,938

)

 

 

1,234

 

 

 

(46,704

)

Depreciation and amortization

 

15,942

 

 

 

14,939

 

 

 

16,965

 

 

 

16,097

 

 

 

17,535

 

 

 

33,024

 

 

 

50,442

 

 

 

64,060

 

 

 

43,608

 

 

 

107,668

 

Other expense

 

 

 

 

1,808

 

 

 

 

 

 

 

 

 

2,660

 

 

 

2,200

 

 

 

2,660

 

 

 

4,008

 

 

 

 

 

 

4,008

 

Loss on extinguishment of debt

 

 

 

 

 

 

 

 

 

 

 

 

 

2,077

 

 

 

 

 

 

2,077

 

 

 

 

 

 

 

 

 

 

Financing related expenses

 

440

 

 

 

 

 

 

392

 

 

 

 

 

 

66

 

 

 

 

 

 

898

 

 

 

 

 

 

 

 

 

 

Acquisition related expenses

 

174

 

 

 

1,056

 

 

 

174

 

 

 

385

 

 

 

65

 

 

 

162

 

 

 

413

 

 

 

1,603

 

 

 

174

 

 

 

1,777

 

Restructuring related expenses

 

(125

)

 

 

 

 

 

566

 

 

 

 

 

 

 

 

 

22,389

 

 

 

441

 

 

 

22,389

 

 

 

4,634

 

 

 

27,023

 

Legal settlement expenses

 

13,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,000

 

 

 

13,000

 

 

 

3,000

 

 

 

(2,900

)

 

 

100

 

Stock-based compensation expense

 

25,096

 

 

 

25,499

 

 

 

26,590

 

 

 

17,897

 

 

 

26,381

 

 

 

32,646

 

 

 

78,067

 

 

 

76,042

 

 

 

28,778

 

 

 

104,820

 

Payroll tax expense related to stock-based compensation

 

879

 

 

 

440

 

 

 

847

 

 

 

405

 

 

 

510

 

 

 

580

 

 

 

2,236

 

 

 

1,425

 

 

 

268

 

 

 

1,693

 

Loss on operating lease assets

 

 

 

 

 

 

 

 

 

 

374

 

 

 

 

 

 

 

 

 

 

 

 

374

 

 

 

979

 

 

 

1,353

 

Adjusted EBITDA

$

62,787

 

 

$

53,237

 

 

$

65,412

 

 

$

53,466

 

 

$

64,964

 

 

$

53,471

 

 

$

193,163

 

 

$

160,174

 

 

$

57,253

 

 

$

217,427

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

$

197,880

 

 

$

183,986

 

 

$

200,610

 

 

$

189,677

 

 

$

195,251

 

 

$

179,958

 

 

$

593,741

 

 

$

553,621

 

 

$

196,644

 

 

$

750,265

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Client contract termination costs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,000

 

 

 

 

 

 

10,000

 

 

 

 

 

 

10,000

 

Adjusted Revenue

$

197,880

 

 

$

183,986

 

 

$

200,610

 

 

$

189,677

 

 

$

195,251

 

 

$

189,958

 

 

$

593,741

 

 

$

563,621

 

 

$

196,644

 

 

$

760,265

 

Net (loss) income margin

 

(0.5

%)

 

 

(1.8

%)

 

 

3.3

%

 

 

31.0

%

 

 

2.0

%

 

 

(21.4

%)

 

 

1.6

%

 

 

3.1

%

 

 

(13.2

%)

 

 

(1.2

%)

Adjusted EBITDA Margin

 

31.7

%

 

 

28.9

%

 

 

32.6

%

 

 

28.2

%

 

 

33.3

%

 

 

28.1

%

 

 

32.5

%

 

 

28.4

%

 

 

29.1

%

 

 

28.6

%

The following tables present a reconciliation of net income (loss) and revenue and calculations of net income (loss) margin and earnings (loss) per share, the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Revenue, Adjusted Net Income Margin, and Adjusted Earnings Per Share, respectively:

(dollars in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net income (loss)

$

3,965

 

 

$

(38,495

)

 

$

9,650

 

 

$

17,001

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Amortization of intangibles related to acquisitions and restructuring activities

 

1,961

 

 

 

21,561

 

 

 

6,837

 

 

 

32,769

 

Other expense

 

2,660

 

 

 

2,200

 

 

 

2,660

 

 

 

4,008

 

Loss on extinguishment of debt

 

2,077

 

 

 

 

 

 

2,077

 

 

 

 

Financing related expenses

 

66

 

 

 

 

 

 

898

 

 

 

 

Acquisition related expenses

 

65

 

 

 

162

 

 

 

413

 

 

 

1,603

 

Restructuring related expenses

 

 

 

 

22,389

 

 

 

441

 

 

 

22,389

 

Legal settlement expenses

 

 

 

 

3,000

 

 

 

13,000

 

 

 

3,000

 

Stock-based compensation expense

 

26,381

 

 

 

32,646

 

 

 

78,067

 

 

 

76,042

 

Payroll tax expense related to stock-based compensation

 

510

 

 

 

580

 

 

 

2,236

 

 

 

1,425

 

Loss on operating lease assets

 

 

 

 

 

 

 

 

 

 

374

 

Income tax effects of excluded items and adjustments for valuation allowance and excess tax benefits/deficiencies from equity awards

 

(5,749

)

 

 

(18,502

)

 

 

(19,385

)

 

 

(75,168

)

Adjusted Net Income

$

31,936

 

 

$

25,541

 

 

$

96,894

 

 

$

83,443

 

Revenue

$

195,251

 

 

$

179,958

 

 

$

593,741

 

 

$

553,621

 

Adjusted to exclude the following:

 

 

 

 

 

 

 

Client contract termination costs

 

 

 

 

10,000

 

 

 

 

 

 

10,000

 

Adjusted Revenue

$

195,251

 

 

$

189,958

 

 

$

593,741

 

 

$

563,621

 

Net income (loss) margin

 

2.0

%

 

 

(21.4

%)

 

 

1.6

%

 

 

3.1

%

Adjusted Net Income Margin

 

16.4

%

 

 

13.4

%

 

 

16.3

%

 

 

14.8

%

Weighted average shares used in computing earnings (loss) per share:

 

 

 

 

 

 

 

Basic

 

379,667

 

 

 

413,437

 

 

 

385,553

 

 

 

412,698

 

Diluted

 

388,504

 

 

 

413,437

 

 

 

393,477

 

 

 

416,450

 

Earnings (loss) per share:

 

 

 

 

 

 

 

Basic

$

0.01

 

 

$

(0.09

)

 

$

0.03

 

 

$

0.04

 

Diluted

$

0.01

 

 

$

(0.09

)

 

$

0.02

 

 

$

0.04

 

Weighted average shares used in computing Adjusted Earnings Per Share:

 

 

 

 

 

 

 

Basic

 

379,667

 

 

 

413,437

 

 

 

385,553

 

 

 

412,698

 

Diluted

 

388,504

 

 

 

420,592

 

 

 

393,477

 

 

 

416,450

 

Adjusted Earnings Per Share:

 

 

 

 

 

 

 

Basic

$

0.08

 

 

$

0.06

 

 

$

0.25

 

 

$

0.20

 

Diluted

$

0.08

 

 

$

0.06

 

 

$

0.25

 

 

$

0.20

 

The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income (loss) measure together with its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense and operating income (loss) as a percentage of revenue, the most directly comparable financial measure calculated in accordance with GAAP:

 

 

 

 

 

 

 

 

 

 

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP

 

Adjusted

 

GAAP

 

Adjusted

 

Three Months Ended
September 30,

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Cost of revenue

$

11,684

 

 

$

18,721

 

 

$

11,596

 

 

$

15,688

 

 

$

36,022

 

 

$

51,755

 

 

$

36,093

 

 

$

48,365

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

6

%

 

 

10

%

 

 

6

%

 

 

8

%

 

 

6

%

 

 

9

%

 

 

6

%

 

 

9

%

Product development and technology

$

30,139

 

 

$

39,611

 

 

$

23,545

 

 

$

24,046

 

 

$

92,010

 

 

$

103,804

 

 

$

72,210

 

 

$

71,426

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

15

%

 

 

22

%

 

 

12

%

 

 

13

%

 

 

15

%

 

 

19

%

 

 

12

%

 

 

13

%

Sales and marketing

$

89,867

 

 

$

91,615

 

 

$

79,961

 

 

$

80,389

 

 

$

273,285

 

 

$

247,577

 

 

$

245,109

 

 

$

234,806

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

46

%

 

 

51

%

 

 

41

%

 

 

42

%

 

 

46

%

 

 

45

%

 

 

41

%

 

 

42

%

General and administrative

$

25,619

 

 

$

35,317

 

 

$

15,185

 

 

$

16,364

 

 

$

94,316

 

 

$

95,144

 

 

$

47,166

 

 

$

48,850

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

13

%

 

 

20

%

 

 

8

%

 

 

9

%

 

 

16

%

 

 

17

%

 

 

8

%

 

 

9

%

Depreciation and amortization

$

17,535

 

 

$

33,024

 

 

$

15,574

 

 

$

11,463

 

 

$

50,442

 

 

$

64,060

 

 

$

43,605

 

 

$

31,291

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

9

%

 

 

18

%

 

 

8

%

 

 

6

%

 

 

8

%

 

 

12

%

 

 

7

%

 

 

6

%

Operating income (loss)

$

20,407

 

 

$

(38,330

)

 

$

49,390

 

 

$

42,008

 

 

$

47,666

 

 

$

(8,719

)

 

$

149,558

 

 

$

128,883

 

% of Revenue (GAAP) /

Adjusted Revenue (Adjusted)

 

10

%

 

 

(21

%)

 

 

25

%

 

 

22

%

 

 

8

%

 

 

(2

%)

 

 

25

%

 

 

23

%

The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income (loss) measure to its most directly comparable financial measure calculated in accordance with GAAP:

 

 

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

195,251

 

 

$

179,958

 

 

$

593,741

 

 

$

553,621

 

Restructuring related expenses

 

 

 

 

10,000

 

 

 

 

 

 

10,000

 

Adjusted Revenue

$

195,251

 

 

$

189,958

 

 

$

593,741

 

 

$

563,621

 

 

 

 

 

 

 

 

 

Cost of revenue

$

11,684

 

 

$

18,721

 

 

$

36,022

 

 

$

51,755

 

Restructuring related expenses

 

 

 

 

(2,878

)

 

 

311

 

 

 

(2,878

)

Stock-based compensation expense

 

(86

)

 

 

(146

)

 

 

(226

)

 

 

(487

)

Payroll tax expense related to stock-based compensation

 

(2

)

 

 

(9

)

 

 

(14

)

 

 

(25

)

Adjusted cost of revenue

$

11,596

 

 

$

15,688

 

 

$

36,093

 

 

$

48,365

 

 

 

 

 

 

 

 

 

Product development and technology

$

30,139

 

 

$

39,611

 

 

$

92,010

 

 

$

103,804

 

Acquisition related expenses

 

(10

)

 

 

(24

)

 

 

(62

)

 

 

(303

)

Restructuring related expenses

 

 

 

 

(8,403

)

 

 

(112

)

 

 

(8,403

)

Stock-based compensation expense

 

(6,384

)

 

 

(6,829

)

 

 

(18,491

)

 

 

(22,952

)

Payroll tax expense related to stock-based compensation

 

(200

)

 

 

(309

)

 

 

(1,135

)

 

 

(720

)

Adjusted product development and technology

$

23,545

 

 

$

24,046

 

 

$

72,210

 

 

$

71,426

 

 

 

 

 

 

 

 

 

Sales and marketing

$

89,867

 

 

$

91,615

 

 

$

273,285

 

 

$

247,577

 

Acquisition related expenses

 

(55

)

 

 

 

 

 

(351

)

 

 

 

Restructuring related expenses

 

 

 

 

(838

)

 

 

(114

)

 

 

(838

)

Stock-based compensation expense

 

(9,725

)

 

 

(10,273

)

 

 

(27,248

)

 

 

(11,665

)

Payroll tax expense related to stock-based compensation

 

(126

)

 

 

(115

)

 

 

(463

)

 

 

(268

)

Adjusted sales and marketing

$

79,961

 

 

$

80,389

 

 

$

245,109

 

 

$

234,806

 

 

 

 

 

 

 

 

 

General and administrative

$

25,619

 

 

$

35,317

 

 

$

94,316

 

 

$

95,144

 

Financing related expenses

 

(66

)

 

 

 

 

 

(898

)

 

 

 

Acquisition related expenses

 

 

 

 

(138

)

 

 

 

 

 

(1,300

)

Restructuring related expenses

 

 

 

 

(270

)

 

 

(526

)

 

 

(270

)

Legal settlement expenses

 

 

 

 

(3,000

)

 

 

(13,000

)

 

 

(3,000

)

Stock-based compensation expense

 

(10,186

)

 

 

(15,398

)

 

 

(32,102

)

 

 

(40,938

)

Payroll tax expense related to stock-based compensation

 

(182

)

 

 

(147

)

 

 

(624

)

 

 

(412

)

Loss on operating lease assets

 

 

 

 

 

 

 

 

 

 

(374

)

Adjusted general and administrative

$

15,185

 

 

$

16,364

 

 

$

47,166

 

 

$

48,850

 

 

 

 

 

 

 

 

 

Depreciation and amortization

$

17,535

 

 

$

33,024

 

 

$

50,442

 

 

$

64,060

 

Amortization of intangibles related to acquisitions and restructuring activities

 

(1,961

)

 

 

(21,561

)

 

 

(6,837

)

 

 

(32,769

)

Adjusted depreciation and amortization

$

15,574

 

 

$

11,463

 

 

$

43,605

 

 

$

31,291

 

 

 

 

 

 

 

 

 

Operating income (loss)

$

20,407

 

 

$

(38,330

)

 

$

47,666

 

 

$

(8,719

)

Amortization of intangibles related to acquisitions and restructuring activities

 

1,961

 

 

 

21,561

 

 

 

6,837

 

 

 

32,769

 

Financing related expenses

 

66

 

 

 

 

 

 

898

 

 

 

 

Acquisition related expenses

 

65

 

 

 

162

 

 

 

413

 

 

 

1,603

 

Restructuring related expenses

 

 

 

 

22,389

 

 

 

441

 

 

 

22,389

 

Legal settlement expenses

 

 

 

 

3,000

 

 

 

13,000

 

 

 

3,000

 

Stock-based compensation expense

 

26,381

 

 

 

32,646

 

 

 

78,067

 

 

 

76,042

 

Payroll tax expense related to stock-based compensation

 

510

 

 

 

580

 

 

 

2,236

 

 

 

1,425

 

Loss on operating lease assets

 

 

 

 

 

 

 

 

 

 

374

 

Adjusted operating income

$

49,390

 

 

$

42,008

 

 

$

149,558

 

 

$

128,883

 

 

Investor Contact

GoodRx

Aubrey Reynolds

ir@goodrx.com

Press Contact

GoodRx

Lauren Casparis

lcasparis@goodrx.com

Source: GoodRx Holdings, Inc.

FAQ

What was GoodRx (GDRX) revenue in Q3 2024?

GoodRx reported revenue of $195.3 million in Q3 2024, representing an 8% increase year-over-year.

What is GoodRx's (GDRX) Q4 2024 revenue guidance?

GoodRx expects Q4 2024 revenue of approximately $200 million, representing about 2% year-over-year growth.

How much net income did GoodRx (GDRX) report in Q3 2024?

GoodRx reported net income of $4.0 million in Q3 2024, with a net income margin of 2.0%.

What is GoodRx's (GDRX) full-year 2024 Adjusted EBITDA guidance?

GoodRx expects full-year 2024 Adjusted EBITDA between $255-260 million, representing 17-20% growth.

GoodRx Holdings, Inc.

NASDAQ:GDRX

GDRX Rankings

GDRX Latest News

GDRX Stock Data

1.93B
98.58M
12.43%
64.91%
2.36%
Health Information Services
Services-computer Processing & Data Preparation
Link
United States of America
SANTA MONICA